S100A10 and metabolic dysfunction-associated steatotic liver disease: Based on both the DEN/DEN-HFD and the LPTENKO models, we identified a crucial protective role for S100A10 on tumoral initiation, in MASLD setting, whereas S100A11 favors growth of tumors in two out of 3 models analyzed.